Awaiting development: Guidance and quality standards

Showing 91 to 100 of 306

Guidance and quality standards awaiting development
Title	Type
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death	Interventional procedures guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance